QLQian Liu

Qian Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qian Liu has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Qinghua Zhou

    Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China

    5 shared publications
  • Evan T. Keller

    Department of Urology and Pathology, School of Medicine, University of Michigan Ann Arbor, Michigan, USA

    2 shared publications
  • Guixiang Liu

    2 shared publications
  • Qinghua Zhou

    Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Xifeng Dong

    Department of Hematology-Oncology, Tianjin Medical University General Hospital, Tianjin, China

    2 shared publications
  • Yi Lu

    Key Laboratory of Longevity and Aging-Related Diseases, Ministry of Education Nanning, China ; Center for Translational Medicine, Guangxi Medical University Nanning, China

    2 shared publications

Latest Publications

  • Open Access

    Review of: "A Bibliometric Review of CSR in China Based on CNKI Database: 2006-2022"

    by Qian Liu

    The authors explored an interesting topic and found some new findings. I would suggest the authors to use more database including Chinese journals, e.g. SCOPUS and Diminsions. Then, they could draw more solid conclusions.

  • Open Access

    Laparoscopy-assisted Distal Gastrectomy should become a Standard Surgical Treatment Option for Stage IA/IB Gastric Cancer

    by Qian Liu

    Gastric cancer (GC) is one of the most commonly occurring and deadly cancers in the world,[1] especially among Chinese.[2] [3] In the early stages of GC, surgery with either subtotal or total gastrectomy, is the first treatment option. Current guidelines recommend open distal gastrectomy (ODG) with D2 lymph node dissection as the standard treatment for stage I GC.[4] [5] However, laparoscopy-assisted distal gastrectomy (LADG), a minimally invasive technique, has become more widely adopted as it results in fewer blood loss, lower pain, and faster recovery than ODG.[6] [7] Previous retrospective studies have reported there were no statistically significant differences in the overall survival of GC patients receiving LADG and those receiving ODG.[8] [9] But selection bias might arise in these studies, because LADG is much more difficult than ODG. Therefore, it is necessary to determine whether LADG is good enough to replace ODG in the treatment of early-stage GC through randomized controlled, noninferiority clinical trials. LADG has become one of the treatment options for stage I GC in the 2017 version of the Gastric Cancer Treatment Guidelines in Japan,[4] as the JCOG0703[10] and JCOG0912[11] clinical trials have confirmed its safety. However, several studies have reported that cancer cells can be recovered in the exhaust gas and instruments used in laparoscopy.[12] [13] These findings suggest that laparoscopy may increase the risk of cancer cells spreading. Thus, the long-term efficacy of LADG is still controversial. In a study recently published in Lancet Gastroenterology & Hepatology, titled “Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial,”[14] JCOG0912 team led by Prof. Hitoshi Katai from the National Cancer Center Hospital in Japan reported the final results of the long-term survival data in JCOG0912 trial to determine if LADG was noninferior to ODG. A total of 921 patients with stage I GC in this study were enrolled between March, 2010 and November, 2013. They were randomly assigned in a 1:1 ratio to receive LADG (n = 462) or ODG (n = 459) at 33 institutions in Japan. Among them, 99% (n = 912) patients successfully received the designated surgery. The 5-year relapse-free survival (RFS) was 95.1% (95% confidence Interval [CI] = 92.7–96.8%) in the LADG group, while that was 94.0% (95% CI = 91.4–95.9%) in the ODG group. LADG was noninferior to ODG for RFS (hazard ratio [HR] = 0.84; 90% CI = 0.56–1.27; p = 0.0075). No patient died because of the surgical treatment. The most commonly occurring postoperative adverse event (AE) was bowel obstruction. There were 5 (1.09%) patients in the LADG group and 11 (2.42%) in the ODG group who developed grade 3 or 4 bowel obstruction. In the previous report of JCOG0912 trial,[11] Prof. Katai and colleagues demonstrated that the frequency of AEs and short-term clinical outcomes of the early-stage GC patients in LADG group were comparable to those in ODG group, but patients receiving LADG lost less blood, recovered faster, and used fewer analgesic doses after surgery than those receiving ODG. Their findings are consistent with the KLASS-01 trial conducted in Korea.[15] Moreover, the long-term data in this study demonstrated that the RFS of the patients treated with LADG is noninferior to those with ODG. The KLASS-01 trial also supports this conclusion.[15] The advantages of this study are as follows: (1) compared with the KLASS-01 trial, this study has a lower proportion of ineligible patients (4% in the KLASS-01 trial, while < 1% in this study) and fewer patients who have not undergone designated surgery (6% in the KLASS-01 trial, while 1% in this study); (2) participants in this study have higher adherence to surgical assignment; (3) under the guidance of the Japan Clinical Oncology Group (JCOG), which is proficient in conducting clinical trials, all details of the JCOG0912 protocol were strictly followed during the study period; (4) due to the high incidence of GC in Japan, Japanese doctors have rich clinical experience in diagnosing and treating GC, so the diagnostic accuracy (4.4% of the study population was found to have higher disease stages than stage I) and the levels of surgical technology in this study are currently the highest in the world. However, this clinical trial has several limitations: (1) the noninferiority HR is 1.54, which is slightly higher than usual in clinical studies; (2) only enrolled stage I GC patients treated by distal gastrectomy; (3) there were approximately 25% patients enrolled in this study received pylorus-preserving gastrectomy (a medical operation that modifies the infrapyloric node dissection and omits the suprapyloric lymph node dissection); (4) the upper limit of CI did not exceed the noninferiority margin, but the CI of HR was wide; (5) it is unclear whether the findings can be applied to non-Japanese patients and used to predict the outcomes of LADG and ODG performed by non-Japanese surgeons. Despite these limitations, this open-label, multicentre, phase III randomized controlled trial has more accurately evaluated if LADG was noninferior to ODG in the treatment of early-stage GC. The findings suggest that LADG should become a standard surgical treatment option for stage I GC. In future clinical trials, the efficacy and safety of LADG for total gastrectomy and for more advanced GC must be accessed. Publication Date: 16 March 2021 (online) © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14,...

  • Open Access

    World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

    by Qian Liu

    Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide in 2020.[1] It poses a significant economic burden in developing countries, especially in China.[2] About 80 to 85% of lung cancers are non–small cell lung cancer (NSCLC).[3] The majority of NSCLC patients will be diagnosed with advanced-stage disease. Therefore, the conventional treatment options, including surgery, chemotherapy, and radiotherapy, are unable to result in complete cures. The prognosis of advanced NSCLC remains poor despite years of research into novel combinations of chemotherapy. Immunotherapy, a new treatment option that uses patient's immune system to fight cancer, holds great promise for cancer patients,[4] including advanced NSCLC patients.[5] [6] Immune checkpoint inhibitors, such as antiprogrammed cell death protein 1 (PD-1) humanized antibody, have become the first-line treatment for advanced NSCLC with programmed death-ligand 1 (PD-L1) expression.[7] [8] [9] The 5-year survival rates of advanced NSCLC patients treated with anti-PD-1 antibodies alone could reach 15.5 to 23.0%.[10] These evidences indicate that blocking the function of PD-1 in T-cells can show a sustained antitumor response in advanced NSCLC patients. However, whether disruption of the PD-1 gene in T-cells of NSCLC patients by gene editing technologies followed by reinfusion of the gene-edited T-cells is therapeutic for advanced NSCLC is still unknown. CRISPR-Cas9 technology is the most flexible and precise gene editing method currently.[11] [12] It edits target DNA by using a guide RNA to help Cas9 recognize the protospacer-adjacent motif upstream or downstream of the target sequence, and then induces Cas9-mediated double-strand breaks in the target DNA. Since CRISPR-Cas9 technology may cause complex genomic alterations and thereby lead to unpredictable consequences,[13] its clinical efficacy is unclear. A recent study published in Science demonstrated the safety and feasibility of CRISPR-engineered T cells in the treatment of refractory cancer.[14] In a study recently published in Nature Medicine, titled “Safety and feasibility of CRISPR-edited T cells in patients with refractory non–small-cell lung cancer,”[15] research team led by Prof. You Lu from West China Hospital conducted a world-first in-human phase I clinical trial (NCT02793856) to access the safety and feasibility of CRISPR-Cas9 PD-1-edited T-cell therapy in advanced NSCLC. In this dose-escalating clinical trial, the authors enrolled 22 advanced NSCLC patients who failed multiple lines of treatment. Among them, 17 (77.3%) patients had sufficient CRISPR-Cas9 PD-1-edited T cells for reinfusion. These patients were divided into four groups (pre-A cohort, cohort A, cohort B, and cohort C). Two patients in pre-A cohort received 2 × 107 PD-1-edited T cells per kg body weight and were monitored for 28 days. After confirming that they had no obvious toxicity, the patients in the other three groups received 1 × 107, 2 × 107, or 4 × 107 PD-1-edited T cells per kg body weight in a series of three reinfusions on day 1, day 3, and day 5, respectively. The authors monitored the off-target risk by analyzing the edited T cells via next generation sequencing and whole-genome sequencing. Additionally, they tracked the edited T cells through evaluating the peripheral T-cell receptor clone diversity and unique T-cell receptor clones in peripheral blood mononuclear cells. The authors found that the edited T cells were detectable in peripheral blood during and following the study treatment. All adverse events due to PD-1-edited T-cell therapy experienced by subjects enrolled were grade ½ suggests that the study treatment was well-tolerated. The median progression-free survival and overall survival was 7.7 weeks (95% confidence interval [CI] = 6.9–8.5 weeks) and 42.6 weeks (95% CI = 10.3–74.9 weeks), respectively. The median frequency of off-target mutation events was 0.05%, ranged from 0 to 0.25%. This study demonstrated for the first time that the clinical application of CRISPR-Cas9 PD-1-edited T-cell therapy is safe and feasible. Additionally, 4 × 107 PD-1-edited T cells per kg body weight given in a 28 days cycle is the final dose. In addition to safety and feasibility, another important concern of this study is the incidence of off-target events. Fortunately, the median mutation frequency of off-target cleavage at all sites detected in this study was very low, and most of these mutations were located in introns or intergenic regions, so it is unlikely to have a significant impact on the coding genes. The low incidence of off-target events may be related to the plasmid electroporation strategy, which is adopted in this study, but this needs to be further verified in future studies. Moreover, it is impossible to examine whether the edited T cells can recognize tumor neoantigens due to the small sample size of this study. This should be verified in future studies too. Additionally, the authors do detected the expression of PD-L1 by immunohistochemistry to ensure that the tumor tissues from all enrolled patients were PD-L1 positive, but actually, the positive expression of PD-L1 does not necessarily correlate with PD-L1 dependency. However, this issue was not further discussed in this study. During the primary cell culture and CRISPR-Cas9 editing of T cells, the authors found that some well-transformed T cells failed to proliferate; in contrast, most of the T cells treated by ribonucleoprotein editing obtained enough cell products successfully. This may be related to the poor quality of T cells collected from heavily treated NSCLC patients. Therefore, for patients with a low frequency of tumor-reactive T cells, the therapeutic efficacy may be limited. In future studies, researchers should use superior gene editing approaches to improve the quantities of tumor-reactive T cells. Overall, the safety and feasibility of CRISPR-Cas9 PD-1-edited T-cell therapy has been demonstrated in a cohort of advanced NSCLC patients. However, considering the limitations of this study, more effective gene-editing technologies should be adopted in future studies. Publication Date: 07 December 2020 (online) © 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Extractant Forced-Circulation Three-Phase Extraction for the Preconcentration of Parts-per-Billion (Ppb)-Level Cadmium(II) from Natural Waters

    by Qian Liu, Qin Yi, Xiang Yi, Bart Van der Bruggen, Lelin Zeng

    An extractant forced-circulation three-phase extraction (EC-TPE) device based on extraction-stripping coupling was developed for the preconcentration of Cd2+ in environmental samples. In this three-phase extraction (W1/O↔O/W2) system, Cd2+ in the sample solution (W1) was fully extracted into the stripping phase (W2) by the circular flow of an organic phase (O↔O). The extraction yield (EY) and enrichment factor (EF) reached almost 100% and 100, respectively, under the following operating conditions: 0.1 M HNO3, 2 mL/L di(2-ethylhexyl)phosphoric acid (P204), circulation flow rate of 32 mL/min, circulation time of 45 min and stirring speed of 400 rpm. An extraction yield of more than 98.5% was still achieved after reusing the organic phase eight times. Two theoretical formulas were established for predicting the EY and EF. Thereafter, EC-TPE was applied in the preconcentration of ppb-level Cd2+ for flame atomic absorption spectrophotometer assay with a detection limit of 0.17 μg/L. Addition/recovery tests for Cd2+ were carried out with recoveries exceeding 98%, and three environmental water samples were accurately analyzed. Finally, application of the EC-TPE device was extended to a different extraction system and other metal ions: Zn2+, Cu2+, Ni2+, and Co2+. The EC-TPE device is easily established utilizing common laboratory glassware, and the enrichment operation efficiency can be conveniently improved by using more than one device simultaneously.

  • [Analysis of the clinical effect on post-stroke shoulder hand syndrome stage Ⅰ treated with the along-meridian trochar acupuncture therapy].

    by Li-Juan Cao, Yan Tan, Wei Zhou, Yuan Li, Hai Hu, Qian Liu, Yu-Wei He, Shuang Tan, Zi-Wei Chen

    To compare the differences in the clinical effect on post-stroke shoulder hand syndrome (SHS) stage Ⅰ between the along-meridian trochar acupuncture therapy and the routine acupuncture therapy with filiform needles. A total of 80 patients with post-stroke SHS stage I were divided into a treatment group (41 cases) and a control group (39 cases) according to the random number table. In the control group, the common filiform needles were used to stimulate Jianyu (LI15), Jianliao (TE14), Jianzhen (SI9), Jianzhongshu (SI15), Jianwaishu (SI14), 5 times a week, 3 weeks as 1 course. In the treatment group, along-meridian trochar acupuncture therapy was applied, 3 times a week, 3 weeks as 1 course. The patients in both groups were all treated with basic medications and routine rehabilitation training. Pain degree, edema degree, upper limb motor function and activity of daily living were observed in the two groups before the treatment, at the end of the treatment and in follow-up. At the end of treatment and in follow-up, the therapeutic effect was evaluated respectively in the patients of the two groups. Compared with the values before treatment, the VAS score of the upper limb was reduced obviously (P< 0.001), the score of the upper limb motor function and Barthel index were increased obviously (PPPPPP<0.001). The along-meridian trochar acupuncture therapy remarkably relieves pain and edema and improves the upper limb motor function and the activity of daily living in the patients with post-stroke shoulder hand syndrome and its clinical therapeutic effect is definite.


  • Open Access

    Translational progress on tumor biomarkers

    by Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou, Jian Zhang

    There is an urgent need to apply basic research achievements to the clinic. In particular, mechanistic studies should be developed by bench researchers, depending upon clinical demands, in order to improve the survival and quality of life of cancer patients. To date, translational medicine has been addressed in cancer biology, particularly in the identification and characterization of novel tumor biomarkers. This review focuses on the recent achievements and clinical application prospects in tumor biomarkers based on translational medicine.


  • Open Access

    A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer

    by Weisan Zhang, Qian Liu, Xifeng Dong, Ping Lei

    A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer


  • Open Access

    Targeting the Notch signaling pathway in cancer therapeutics

    by Huajiao Guo, Yi Lu, Jianhua Wang, Xia Liu, Evan T. Keller, Qian Liu, Qinghua Zhou, Jian Zhang

    Despite advances in surgery, imaging, chemotherapy, and radiotherapy, the poor overall cancer‐related death rate remains unacceptable. Novel therapeutic strategies are desperately needed. Nowadays, targeted therapy has become the most promising therapy and a welcome asset to the cancer therapeutic arena. There is a large body of evidence demonstrating that the Notch signaling pathway is critically involved in the pathobiology of a variety of malignancies. In this review, we provide an overview of emerging data, highlight the mechanism of the Notch signaling pathway in the development of a wide range of cancers, and summarize recent progress in therapeutic targeting of the Notch signaling pathway.